Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Leukemia, chronic lymphocytic (CLL)
Stage/Subtype:  stage III chronic lymphocytic leukemia
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 99 for your search:
Start Over
Autologous Peripheral Blood Stem Cell Transplant in Treating Patients with Lymphoma
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT 2004-24, NCI-2010-01414, 0508M72589, 2005LS048, UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD
Status: Active
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 471501, NCI-2016-01887, NCT02956122
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Status: Enrolling by invitation
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR100955, NCI-2013-02262, 2012-004225-24, PCI-32765CAN3001, NCT01804686
Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Untreated and Previously Treated Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: UTX-TGR-304, NCI-2016-00375, NCT02612311
Transplantation of Ex Vivo Expanded, UCB-derived, Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 16 to 60
Trial IDs: GC P#05.01.020, NCI-2016-01518, NCT02730299
Efficacy and Safety of Maribavir in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 12 and over
Trial IDs: SHP620-303, NCI-2016-01720, 2015-004725-13, NCT02931539
Lenalidomide and AT-101 in Treating Patients with Relapsed B-Cell Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MC128A, NCI-2009-01569, NCT01021345, NCT01003769
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TED10893, NCI-2010-02332, U1111-1116-5472, NCT01084252
Allogeneic Stem Cell Transplant for Chronic Lymphocytic Leukemia (CLL)
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 2012-0249, NCI-2012-01248, NCT01629511
Inotuzumab Ozogamicin, Fludarabine Phosphate, Bendamustine Hydrochloride, and Rituximab before Donor Stem Cell Transplant in Treating Patients with Lymphoid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: 2012-0265, NCI-2012-02072, NCT01664910
Azacitidine in Treating Patients Undergoing Matched Unrelated Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 201303012, NCI-2012-03105, NCT01747499
Phase 1/2A Dose Escalation Study in CLL, SLL or NHL
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-601, NCI-2014-00784, NCT01994382
Partially-Matched Donor Stem Cell Transplant in Treating Younger Patients with High-Risk Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Not specified
Trial IDs: SCT 0813, NCI-2015-00141, CMH SCT 0813, CMH 13H11, NCT02053545
Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA224-022, NCI-2014-01120, NCT02061761
Ibrutinib and Obinutuzumab in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 65 and over
Trial IDs: GA101 + Ibrutinib, NCI-2015-02052, 141106, NCT02315768
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-LY-005, NCI-2015-01019, NCT02362035
A Phase 1/2, Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: INCB 57643-101, NCI-2016-01069, NCT02711137
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: eFT508-0002, NCI-2017-00209, NCT02937675
Combination Study of IPH2201 With Ibrutinib in Patients With Relapsed, Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IPH2201-202, NCI-2017-00298, NCT02557516
Low-Dose Chemotherapy, Low-Dose Total-Body Irradiation, and Anti-Thymocyte Globulin Followed by Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancy or Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2001-10, NCI-2010-02155, 2001LS058, 0108M06725, UMN-2001LS058, UMN-MT2001-10, NCT00303719
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation and Anti Thymocyte Globulin before Umbilical Cord Blood Transplantation in Treating Patients with Hematological Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2005-02, NCI-2010-01415, 2005LS036, UMN-2005LS036, UMN-MT-2005-02, UMN-0507M70121, NCT00305682
Donor Peripheral Blood Stem Cell or Bone Marrow Transplant in Treating Patients With Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 55 and under
Trial IDs: MT1999-14, NCI-2010-02157, 1999LS060, UMN-1999LS060, UMN-MT1999-14, NCT00612716
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2008-0385, NCI-2009-01510, Celgene # RV-CLL-PI-0223, NCT00628238
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients with Hematologic Disease
Status: Active
Phase: Phase II
Type: Treatment
Age: 6 months to 45 years
Trial IDs: 2010.00, NCI-2010-00190, FHCRC 2010.00, 2010, Protocol 2010, 6095, NCT00719888
Start Over